Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2011

01-02-2011 | Letter

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Authors: Cristina Oliveras-Ferraros, Sílvia Cufí, Tamara Sauri-Nadal, Sonia Del Barco, Begoña Martin-Castillo, Alejandro Vazquez-Martin, Javier A Menendez

Published in: Breast Cancer Research | Issue 1/2011

Login to get access

Excerpt

In the previous issue of Breast Cancer Research, Jin and colleagues [1] demonstrated that the lipogenic enzyme fatty acid synthase (FASN) is phosphorylated when it is in complex with the tyrosine kinase receptor HER2. HER2-dependent activating phosphorylation of FASN was related to tumor progression and was sensitive to the dual HER1/HER2 tyrosine kinase inhibitor lapatinib [1]. Adding to knowledge of the therapeutic value of the phosphorylation status of FASN in HER2-driven breast cancer (BC), we now provide experimental evidence that the expression status of FASN in the extracellular milieu (that is, extracellular FASN) may function as a novel biomarker that distinctively predicts molecular functioning of lapatinib. …
Appendix
Available only for authorised users
Literature
1.
Jin Q, Yuan LXH, Boulbes DR, Baek J-M, Wang Y-N, Gomez-Cabello D, Hawke DH, Yeung S-C, Lee M-H, Hortobagyi GN, Hung M-C, Esteva FJ: Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010, 12: R96-10.1186/bcr2777.CrossRefPubMedPubMedCentral
2.
Oliveras-Ferraros C, Vazquez-Martin A, Fernández-Real JM, Menendez JA: AMPK-sensed cellular energy state regulates the release of extracellular fatty acid synthase. Biochem Biophys Res Commun. 2009, 378: 488-493. 10.1016/j.bbrc.2008.11.067.CrossRefPubMed
3.
Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS: Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle. 2008, 7: 1769-1775. 10.4161/cc.7.12.6016.CrossRefPubMed
4.
Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA: Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol. 2009, 35: 1369-1376.PubMed
Metadata
Title
Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
Authors
Cristina Oliveras-Ferraros
Sílvia Cufí
Tamara Sauri-Nadal
Sonia Del Barco
Begoña Martin-Castillo
Alejandro Vazquez-Martin
Javier A Menendez
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2799

Other articles of this Issue 1/2011

Breast Cancer Research 1/2011 Go to the issue

Research article

A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation

Editorial

Breast cancer genome heterogeneity: a challenge to personalised medicine?

Research article

During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein

Research article

Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers

Letter

Circulating microRNAs: promising breast cancer biomarkers - authors' response

Research article

α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits